Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Sun Pharma: Outpacing continues - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Jul 30, 2001

    Sun Pharma: Outpacing continues

    Sun Pharma has reported a net profit growth of 34% in 1QFY02 mainly on the back of better product mix. Operating margins have inched up further to 27.9%, increasing by 80 basis points. Operating margins of the company continue to be the best in the industry, due to strong brand presence in high margin cardiovascular segment.

    (Rs m) 1QFY01 1QFY02 Change FY01
    Sales 1,327 1,672 26.0% 6,132
    Other Income 5 10 98.0% 67
    Expenditure 967 1,205 24.6% 4,625
    Operating Profit (EBDIT) 360 467 29.9% 1,507
    Operating Profit Margin (%) 27.1% 27.9%   24.6%
    Interest (3) (8.7) 163.6% (21)
    Depreciation 38 41 10.1% 152
    Profit before Tax 330 444.1 34.5% 1,444
    Other Adjustments   -   -
    Tax 20 29 46.9% 95
    Profit after Tax/(Loss) 311 415 33.7% 1,349
    Net profit margin (%) 23.4% 24.8%   22.0%
    No. of Shares (eoy) (m) 46.8 46.8   46.8
    Diluted Earnings per share* 26.5 35.5   28.9
    P/E (at current price)   17.1   21.0

    Domestic branded formulations grew by 26%, which has come as a positive surprise. In domestic branded business, the company launched 11 products in the quarter across various high margin therapeutic segments such as cardiovascular, diabetes, opthalmology and arthritis. Exports grew by 90%, helped largely by the company's merger with Sun Pharma Exports. However, excluding the merger effect export growth was sluggish. Caraco Pharma, the US affiliate of the company has posted a loss of US$ 1.7 m for the quarter ended in March'01. The mounting losses of Caraco is a major concern for Sun Pharma. Caraco Pharma has recently received 3 FDA approvals, which may help the company to come out of the red.

    At Rs 528 the company trades on a multiple of 17x annualised earnings for 1QFY02. The low valuations accorded to the stock compared to its peers in the sector appear mainly on account of Caraco losses, which remain the biggest trigger for the stock.



    Equitymaster requests your view! Post a comment on "Sun Pharma: Outpacing continues". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

    Mar 11, 2017

    Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 18, 2017 11:25 AM


    • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks


    Compare Company With Charts